Track topics on Twitter Track topics that are important to you
MONCTON, NEW BRUNSWICK -- (Marketwired) -- 03/01/17 -- Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF) (the "Company") has appointed a medical marijuana, pharmaceutical, and biotechnology industry veteran as its new chief executive officer.
Greg Engel will assume his new role effective March 13, 2017. Mr. Engel succeeds Organigram's current CEO Denis Arsenault who is stepping up to the newly created executive chairman's position. Engel will also join the Board of Directors of Organigram, replacing Larry Rogers, who steps down from the Board, but remains an important part of the Senior Management team.
Engel, 52, has served in a number of senior-level and executive positions in related industries over the past 25 years in Canada, US and Internationally. Most recently he was chief executive officer for Tilray Canada Inc., an early medical marijuana leader and the first Canadian company to export medical cannabis products to Europe.
"We consider ourselves extremely fortunate to find and recruit Greg," said Arsenault. "Greg emerged as the leading candidate following an international search. His experience and leadership will be instrumental as we enter the next phase of our growth."
Currently based in Toronto, Engel is familiar with Moncton having served as district sales manager in the pharmaceutical industry earlier in his career.
"I consider this appointment an outstanding opportunity," he said. "Organigram is poised to become one of the world's leading marijuana producers; it will be gratifying to be part of a leadership team that helps the company achieve its goals."
Engel is a native of Picton, ON and earned an Honours Bachelor of Science degree in Microbiology from the University of Guelph in 1987 and then studied marketing at Queen's University. He has also attended York University's Schulich School of Business.
For his part, Arsenault said the decision to turn the day-to-day management of Organigram over to an executive of Engel's calibre has been planned for some time. "It has been 3 years to the day since I joined Organigram and I've achieved most of my goals as company CEO and believe it's time for me to pass the torch to a seasoned Executive with demonstrated leadership skills" he said. "I will stay active in the areas of Investor Relations and Capital Markets and look forward to working with Greg as he leads us through our next phase of expansion" he concluded.
Arsenault also wanted to acknowledge the leadership of Monique Imbeault, who was Chairwoman of the Board over the past year, and remains an important part of our Board of Directors moving forward.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.Contacts: Organigram Holdings Inc. Denis Arsenault Executive Chairman Organigram Holdings Inc. Giselle Doiron Director of Investor and Media Relations (506) 801-8986 NEXT ARTICLE
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Microbiology (from Greek μῑκρος, mīkros, "small"; βίος, bios, "life"; and -λογία, -logia) is the study of microscopic organisms, either unicellular (singl...